Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Prognostic Value of the Measurable Residual Disease (MRD)... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
0
Authors
Carlos Jiménez‐Vicente
25 more
Carlos Jiménez‐Vicente
•
Aina Cardús
23 more
•
Jordi Esteve
Published
November 5, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Blood
Topics
Biology
Biochemistry
Medicine
Cancer Oncology
Internal Medicine
Show all topics
DOI
10.1182/blood-2024-204503
